Context: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with overall poor prognosis. The Ki67 labeling index (LI) has a major prognostic role in localized ACC after complete resection, but its estimates may suffer from considerable intra-and interobserver variability. VAV2 overexpression induced by increased Steroidogenic Factor-1 dosage is an essential factor driving ACC tumor cell invasion.
immunohistochemical markers were correlated with progression-free survival (PFS) and overall survival (OS).
Results: VAV2 expression and Ki67 LI were significantly correlated with each other and with PFS and OS. Heterogeneity of VAV2 expression inside the same tumor was very low. Combined assessment of VAV2 expression and Ki67 LI improved patient stratification to low-risk and high-risk groups.
Conclusion: Combined assessment of Ki67 LI and VAV2 expression improves prognostic prediction in ACC. (J Clin Endocrinol Metab 102: [3491] [3492] [3493] [3494] [3495] [3496] [3497] [3498] 2017) A drenocortical carcinoma (ACC) is a rare endocrine malignancy with overall poor prognosis, limited treatment options when progressed into metastatic stage, and unsatisfactory response to polychemotherapeutic cytotoxic regimens (1, 2) . Hence the most efficient method to eradicate the disease consists in complete surgical resection of the primary tumor. However, risk of recurrence is high even in this condition. Molecular studies have identified two subclasses of ACCs with aggressive or indolent clinical behavior (3) (4) (5) (6) . However, because molecular markers identified by those studies have not yet found entrance into clinical practice, it would be of particular importance to stratify patients with ACC into low-or high-risk groups to adequately monitor disease recurrence and assign them to appropriate therapeutic interventions. The histological Weiss score, which is commonly used as an established morphometric criterion for differential diagnosis in adrenocortical tumors, has limited value as a prognostic indicator, especially in cases with borderline features (7, 8) . Conversely, it was shown that several immunohistochemical markers have a prognostic value in ACC (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Among those, the most widely used in clinical pathology reports is the Ki67 labeling index (LI), which is directly related to the proliferative activity of a given tissue (14) (15) (16) (17) (18) . A study recently completed by the European Network for the Study of Adrenal Tumors (ENS@ T) could indeed demonstrate that Ki67 LI has a major prognostic role in localized ACC after complete resection (18) . However, Ki67 LI estimates suffer from considerable intra-and interobserver variability, as highlighted in a recent study (19) . New prognostic markers are needed, therefore, to further refine prognostic classification of patients with ACC as part of a multiparametric analysis.
The transcription factor Steroidogenic Factor-1 (SF-1) has a pivotal role in regulating adrenocortical cell proliferation and differentiation (20) . Its overexpression is associated with adrenocortical tumorigenesis through regulation of a specific set of SF-1 dosage-dependent target genes (21, 22) . One of these genes encodes VAV2, a guanine nucleotide exchange factor for small GTPases of the Rho family (23) . We have recently shown that VAV2 overexpression induced by an increased SF-1 dosage in ACC is an essential factor driving tumor cell invasion (24) .
Herein, we present the results of a large study involving ACC cases provided by seven European institutions aimed to assess the prognostic value of VAV2 expression in ACC and to compare and integrate it with the Ki67 LI.
Materials and Methods
Immunostaining on formalin-fixed, paraffin-embedded ACC samples
We analyzed 171 adrenocortical tumor tissues from patients with ACC provided by seven ENS@T centers (three centers in Italy, n = 103 samples; two in The Netherlands, n = 42; one in France, n = 20; one in Germany, n = 6). A total of 145 samples were previously assembled in seven tissue microarrays (TMAs) with two or three cores per sample interspersed with normal human liver, kidney, and placenta tissues; 26 samples were available as full slides. Among the ACC samples, 157 were derived from primary tumors (male/female, 59:98; average age 6 standard deviation [SD], Figure 1 . Examples of various intensities of VAV2 staining in ACC specimens. The H-score value is indicated for each image. Scale bar, 400 mm (images in left column); 50 mm (images in right column).
48.7 6 15.2 years; average tumor size 6 SD, 11.2 6 5.4 cm; Supplemental Table 1 )-six from local recurrences and eight from distant metastases (liver and lung). The diagnosis of ACC was made by established criteria based on clinical, biochemical, and morphological data (25) . All clinical data were collected through the ENS@T database (registry.ensat.org). All patients gave informed consent and the study was approved by ethical committees from all participating institutions.
Immunohistochemical detection was performed on all samples using an indirect immunoperoxidase technique after hightemperature antigen retrieval in 0.01 M citrate buffer (pH 6.5) in a pressure cooker for 13 minutes. The primary antibody was a rabbit monoclonal antibody against the VAV2 protein (clone EP1067Y, catalog no. ab52640; Abcam) diluted 1:250 in 25% AB serum in phosphate-buffered saline and incubated for 1 hour at room temperature. Signal detection was performed with the ADVANCE HRP detection system (Dako) and 3,3 0 -diaminobenzidine chromogen according to the manufacturer's instructions. Nuclei were counterstained with Mayer hematoxylin for 3 minutes. As negative control, universal rabbit negative control (Dako) was used.
Immunostaining results were analyzed using a light microscope at high magnification. VAV2 staining intensity was evaluated independently by two investigators blinded to the clinical data (S.S. and I.S.). Cytoplasmic staining intensity was evaluated with a grading score of 0, 1, 2, or 3, corresponding to negative, weak, moderate, and strong intensity, respectively. The proportion of positive tumor cells was calculated for each specimen and set up to be scored 0, 0.1, 0.5, or 1, if 0%, 1% to 9%, 10% to 49%, or .50% of the tumor cells were positive for VAV2, respectively. A semiquantitative H-score was then calculated by multiplying the staining intensity grade by the proportion score (12, 24) .
In all cases analyzed, the proportion of VAV2 positive cells was always .50%, so all intensity values were multiplied by a factor equal to 1 to yield the H-score. The cutoff point to separate samples in high or low VAV2 expression was between H-scores ,2 and $2. Ki67 LI data assessed by the local pathologists in each expert center were retrieved from the ENS@T database. The Ki67 LI cutoff value used in this study to separate low LI and high LI groups was 20%.
Statistical analysis
Correlation analyses were performed using a x 2 test for categorical variables. The interobserver agreement for the scoring system was evaluated using the Cohen k coefficient and confirmed using Pearson correlation coefficient. The cutoff for strong agreement chosen for the k coefficient was 0.81, and 0.75 was chosen for the Pearson coefficient (26) . The comparison of clinical and histopathological characteristics was performed on GraphPad Prism 6.0 software using a nonparametric MannWhitney test (for two groups) and Kruskal-Wallis test with Dunn correction for multiple testing (for more than two groups), as appropriate. A P value ,0.05 was considered to be statistically significant. Survival analysis for patients with ACC was calculated as described (24) using the Kaplan-Meier method, and differences between groups were assessed with log-rank and Cox proportional hazards statistics, using the SPSS software package (version 23.0.0 for Mac; IBM), after adjustment for sex, age, and tumor stage. Progression-free survival (PFS) was defined as time elapsed from primary resection of ACC to the first recurrence, locoregional or systemic. Overall survival (OS) was defined as time elapsed from primary resection of ACC to disease-related death or last follow-up visit. In the group of patients with R0 resection, OS data relative to VAV2 expression and Ki67 LI were available for 100 and 105 patients, respectively. Of those patients, 92 had both VAV2 and Ki67 LI OS data available. Viable cell data after VAV2 knockdown were analyzed by one-way analysis of variance with Dunnett correction for multiple comparisons.
Results

VAV2 expression is a strong predictor of PFS and OS in patients with ACC
Examples of different VAV2 expression patterns in ACC are shown in Fig 1. An H-score was assigned to each sample, which took into consideration both staining intensity and the percentage of cells stained by the anti-VAV2 antibody. The interobserver agreement was very good, with the Cohen k coefficient equal to 0.85 [95% confidence interval (CI), 0.72 to 0.89] and Pearson coefficient r equal to 0.90 (95% CI, 0.86 to 0.93; P , 0.001). In contrast to Ki67 staining, which is usually heterogeneous throughout a tumor, VAV2 expression was fairly equally distributed within a given tumor, with all samples presenting .50% stained cells. H-score heterogeneity among different TMA tissue cores belonging to the same tumors was limited, with a residual SD s equal to 0.14 and an intraclass correlation coefficient a equal to 0.95 (95% CI, 0.92 to 0.97; Supplemental Fig. 1 ). The same homogenous distribution was also observed when whole tumor slides were analyzed (Fig 1) .
VAV2 expression in the tumor was strongly correlated to both PFS [Fig 2(a) ] and OS [Fig 2(b) ], confirming the results of our previous study performed on an independent smaller cohort of patients with ACC (24) . Patients with strong VAV2 expression had a 2.8-fold higher risk of experiencing a recurrence and 1.6-fold increased risk of dying. No statistically significant difference existed for VAV2 expression in primary tumors and metastatic sites from the same patients (P = 0.67). The Ki67 LI was also a strong predictor of PFS [Fig 2(c) ] and OS [Fig 2(d) ], as reported in previous studies (14) (15) (16) (17) (18) . Both VAV2 expression and Ki67 LI were strongly correlated with OS even in patients with R0 resection (Supplemental Fig. 2 ). VAV2 expression and Ki67 LI had a similar strong prognostic value for PFS and OS both in univariate and in multivariate analyses, taking into account patients' age, sex, and tumor stage (Table 1) .
Combined assessment of VAV2 expression and Ki67 LI improves prognostic power
In general, a significant correlation existed between Ki67 LI and VAV2 expression in our ACC cohort (Supplemental Fig. 3) . A strong correlation also existed when Ki67 LI and VAV2 expression were considered as categorical (low vs high) variables (x 2 = 6.18; P = 0.01).
However, in several cases, these two parameters were Fig 3(c) and 3(d) ]. This type of stratification maintained a strong prognostic value even in R0 patients (Supplemental Fig. 4) . Remarkably, when considering the high-risk group apart from all other patients with ACC, a very strong correlation existed with OS in the whole cohort [Fig 4( 
Discussion
The prognosis of patients with ACC is variable and poorly predictable. A recent, large multicenter ENS@T study has shown that the KI67 LI is the most powerful parameter predicting disease recurrence and survival in patients with ACC after complete tumor resection (18) . The Ki67 LI has been integrated with the combined evaluation of morphological parameters (i.e., number of mitoses/presence of necrosis) in the newly introduced Helsinki score, which reportedly more accurately predicts recurrence in ACC (8, 27) . However, even if Ki67 LI assessment is routinely performed in diagnostic pathology laboratories for many neoplastic disorders, its standardization and reproducibility have been questioned for many tumor types, including ACC (19) . It is important, therefore, to identify other molecular markers that can complement the Ki67 LI to obtain a more accurate stratification of the risk of recurrence in patients with ACC. In this perspective, molecular prognostic indicators derived from genomic studies are very promising (3, 28, 29) , but for routine implementation, they suffer from the important drawback that, at least at the present state of technology, frozen tumor material is required. On the other hand, prognostic value of circulating markers of malignancy awaits validation in large cohorts of patients with ACC (30) (31) (32) (33) .
We have recently shown that VAV2 overexpression is an essential driver of cell invasion in conditions of increased SF-1 dosage through its guanine nucleotide exchange factor activity for the small GTPases Rac1 and Cdc42 (24) . Those data directly link VAV2 with the potential mechanism of malignancy consisting of increased cellular invasiveness. In the current study, we extended the previous study to a large European cohort of patients with ACC and show that the tumor VAV2 Hscore is significantly correlated to PFS and OS. The combined assessment of VAV2 expression and Ki67 LI improves patient risk stratification, with cases presenting high Ki67 LI but low VAV2 expression having significantly longer PFS and OS compared with patients with concordant high-risk parameters. In our study, VAV2 Hscore assessment, which was mainly performed on TMA tissue cores, was associated with an excellent intratumoral reproducibility and is, in principle, less prone to intra-and interobserver variability, although further work is needed to specifically address this question on an even larger number of cases. These results show that immunohistochemical assessment of VAV2 expression may usefully complement the measurement of the Ki67 LI for prognostic stratification of patients with ACC.
